000520 — Samil Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00- KR₩224bn
- KR₩382bn
- KR₩220bn
- 14
- 33
- 35
- 13
Annual income statement for Samil Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 122,999 | 134,247 | 179,676 | 196,346 | 219,700 |
| Cost of Revenue | |||||
| Gross Profit | 49,032 | 48,988 | 67,486 | 74,071 | 80,914 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 116,461 | 133,847 | 175,656 | 190,458 | 219,545 |
| Operating Profit | 6,538 | 400 | 4,020 | 5,888 | 154 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 1,198 | -4,761 | 1,058 | 1,424 | -3,613 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 1,341 | -5,347 | -28.3 | 1,664 | -5,629 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 1,341 | -5,347 | -28.3 | 1,664 | -5,629 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 1,341 | -5,347 | -28.3 | 1,664 | -5,629 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 101 | -404 | -10.4 | 65.3 | -314 |
| Dividends per Share |